Viral vaccines for dengue: The present and the future

Dengue Bulletin

Volumn 27, Issue , 2003, Pages 181-191

  Swaminathan, S ^a   Khanna, Navin ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

Author keywords

Adenovirus; Dengue vaccine; Dengue virus

Indexed keywords

ADENOVIRUS VECTOR; CELL SURFACE RECEPTOR; COMPLEMENTARY DNA; DENGUE VACCINE; LIVE VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; STRUCTURAL PROTEIN; VIRUS ANTIGEN; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ARTICLE; CLINICAL TRIAL; DENGUE; DENGUE VIRUS; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; ENDEMIC DISEASE; FLAVIVIRUS; GENE TECHNOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNITY; MOLECULAR CLONING; MONKEY; NONHUMAN; PHENOMENOLOGY; PROTECTION; RISK ASSESSMENT; SEROTYPE; SIDE EFFECT; TISSUE CULTURE; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS INTERFERENCE; VIRUS RECOMBINANT; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION; YELLOW FEVER FLAVIVIRUS;

ADENOVIRIDAE; DENGUE VIRUS; DENGUE VIRUS GROUP; FLAVIVIRUS; VACCINIA VIRUS; YELLOW FEVER VIRUS;

EID: 3042842664     PISSN: 1020895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Gubler DJ, Epidemic dengue/dengue haemorrhagic fever: A global public health problem in the 21st century. Dengue Bulletin, 1997, 21: 1-15.
2. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis, 1994, 19: 500-512.
3. Halstead SB and Deen J. The future of dengue vaccines. Lancet, 2002, 360; 1243-1245.
4. Almond J, Clemens J, Engers H, Halstead S, Khiem HB, Pablos-Mendez A, Pervikov Y and Tram TT. Meeting report: Accelarating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City, Vietnam, Vaccine, 2002, 20: 3043-3046.
5. Raviprakash K, Kochel TJ, Ewing D, Simmons M, Phillips I, Hayes CG and Porter KR. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full-length envelope protein. Vaccine, 2000, 18: 2426-2434.
6. Trent DW, Kinney RM and Huang CY-H. Recombinant dengue vaccines in "Dengue and dengue haemorrhagic fever" (Gubler DJ and Kuno G, Eds.). 1997, 379-403, CAB Inernational, Wallingford
7. Thalhamer J, Leitner W, Hammerl P and Brtko J. Designing immune responses with genetic immunization and immunostimulatory DNA sequences. Endocrine regulations, 2001, 35: 143-166.
8. Rolph MS and Ramshaw IA. Recombinant viruses as vaccines and immunological tools. Current Opin Immunol, 1997, 9: 517-524.
9. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang Z-X, Weltzin R, Geogakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, and Monath TP. Construction, safety, and immunogenicity in nonhuman primates of chimeric yellow fever-dengue virus tetravalent vaccine. J Virol, 2001, 75: 7290-7304.
10. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang Z-X, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K and Monath TP, Viraemia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: Generic reconstruction, dose adjustment and antibody responses against wild-type dengue virus isolates. Virology, 2002, 298: 146-159.
11. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis Bl, Saluzzo J-F and Hoke Jr CH, Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers, Vaccine, 2001, 19: 3179-3188.
12. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, Jagsudee A, Saluzzo J-F and Bhamarapravati N. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: Role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg, 2002, 66: 264-272.
13. Chen Y, Maguire T and Marks RM. Demonstration of binding of dengue virus envelope protein to target cells. J Virol, 1996, 70:8765-8772.
14. Mégret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, Murray JM, Schlesinger JJ, Wright PJ, Young P, van Regenmortel MHV and Deubel V. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue envelope glycoprotein. Virology, 1992, 187: 480-491.
15. Churdboonchart V, Bhamarapravati N, Peampramprecha S and Srinavin S. Antibodies against dengue viral proteins in primary and secondary dengue homorrhagic fever. Am J Trop Med Hyg, 1991, 44:481-493.
16. Crill WD and Roehrig RT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol, 2001, 75: 7769-7773.
17. Kaufman BM, Summers PL, Dubois DR and Eckels KH. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg, 1987, 36: 427-434.
18. Feighny R, Burrous J, McCown J, Hoke C and Putnak R. Purification of native dengue-2 viral proteins and the ability of purified proteins to protect mice. Am J Trop Med Hyg, 1992, 47: 405-412.
19. Guirakhoo F, Bolin RA and Roehrig JT. The Murray valley encephalitis virus prM protein confers acid resitance to virus particles and alters the expression of epitopes within the R2 domain of the E glycoprotein. Virology, 1992, 191: 921-931.
20. Lai CJ, Bray M, Men R, Cahour A, Chen W, Kawano H, Tadano M, Hiramatsu K, Tokimatsu I, Pletnev A, Arakai S, Shameem G and Rinaudo M. Evaluation of molecular strategies to develop a live dengue vaccine. Clin Diagn Virol, 1998, 10: 173-179.
21. Markoff L, Pang X, Houng H-S, Falgout B, Olsen R, Jones E and Polo S. Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J Virol, 2002, 76: 3318-3328.
22. Whitehead SS, Falgout B, Hanley KA, Blaney Jr JE, Markoff L and Murphy BR. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ unstranlated region is highly attenuated and immunogenic in monkeys. J Virol, 2003, 77: 1653-1657.
23. Huang CY-H, Butrapet S, Pierro DJ, Chang G-JJ, Hunt AR, Bhamarapravati N, Gubler DJ and Kinney RM. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus vaccine. J Virol, 2000, 74: 3020-3028.
24. Butrapet S, Huang CY-H, Pierro DJ, Bhamarapravati N, Gubler DJ and Kinney RM Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and non-structural proteins 1 and 3. J Virol, 2000, 74: 3011-3019.
25. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai C-J, Elkins WR, Chanock RM, Murphy BR and Whitehead SS. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30-nucleotide deletion in its 3′-unstranslated region. Am J Trop Med Hyg, 2001, 65: 405-413.
26. Monath TP. Yellow fever in "Vaccines" 3rd edition (Plotkin SA and Orenstein WA, Eds.). WB Saunders Co, Philadelphia, 1997: 815-880.
27. Kelly EP, Greene JJ, King AD and Innis BL. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine, 2000, 18: 2549-2559.
28. Men R, Wyatt L, Tokimatsu I, Arakaki S, Shameem G, Elkins R, Chanock R, Moss B, and Lai C-J. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resitance to dengue type 2 virus challenge. Vaccine, 2000, 18: 3113-3122.
29. Kost TA and Condreay JP. Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends Biotechnol, 2002, 20: 173-180.
30. Stephenson J. Defective adenoviruses as novel vaccines for the Flaviviridae. Clin Diagn Virol, 1998, 10: 187-194.
31. Bray M, Zhao BT, Markoff L, Eckels KH, Chanock RM and Lai C-J. Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis. J Virol, 1989, 63: 2853-2856.
32. Lai C-J, Zhang YM, Men R, Bray M, Chanock RM, Dubois DR and Eckels KH. Immunization of monkeys with baculovirus recombinant-expressed dengue envelope and NS1 glycoproteins induces partial resistance to challenge with homotypic dengue virus in "Modern approaches to new vaccines, including prevention of AIDS" (Chanock RM, Ginsberg HS, Brown F and Lerner RA, Eds.), CSHL Press, Cold Spring Harbor, NY, 1991, 251-257.
33. Men RH, Bray M and Lai C-J. Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit-increased immunogenicity in mice. J Virol, 1991, 65: 1400-1407.
34. Bray M and Lai C-J Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology, 1991, 185: 505-508.
35. Ertl HCJ and Xiang Z. Novel vaccine approaches. J Immunol, 1996, 156:3579-3582.
36. Polo JM and Dubensky Jr TW Virus-based vectors for human vaccine applications. Drug Discovery Today, 2002, 7: 719-727.
37. Gaydos CA and Gaydos JC. Adenovirus vaccines in "Vaccines" 3rd edition (Plotkin SA and Orenstein WA, Eds), WB Saunders Co, Philadelphia, 1999: 609-628.
38. Horwitz MS. Adenoviruses in "Fields Virology" 4th edition (Knipe DM. and Howley PM, Eds-in-Chief), Lippincot Williams and Wilkins, Philadelphia, 2001: 2301-2326.
39. Wang Y and Huang S. Adenovirus technology for gene manipulation and functional studies. Drug Discovery Today, 2000, 5: 10-16.
40. Top FH, Grossman RA, Bartelloni PJ, Segal HE, Dudding BA, Russell PK and Buescherr EL. Immunization with live type 7 and 4 vaccines. I. Safety, infectivity, antigenity and potency of adenovirus type 7 vaccine in humans. J Infect Dis, 1971a, 124: 148-154.
41. Top FH, Buescher EL, Bancroft WH and Russell PK. Immunization with live type 7 and 4 vaccines. II Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis, 1971b, 124: 155-160.
42. Imler J-L. Adenovirus vectors as recombinant viral vaccines. Vaccine, 1995, 13: 1143-1151.
43. Gonin P, Oualikene W, Fournier A and Eloit M. Comparison of the efficacy of replication-defective adenovirus and NYVAC poxvirus as vaccine vectors in mice. Vaccine, 1996, 14: 1083-1087.
44. Xiang ZQ, Yang YP, Wilson JM and Ertl H. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology, 1996, 219: 220-227.
45. Shiver JW, Fu T-M, Chen L, Casimiro DR, Davies M-E, Evans RK, Zhang Z-Q, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC and Emini E A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature, 2002, 415, 331-335.
46. Hitt MM, Addison CL and Graham FL. Human adenovirus vectors for gene transfer into mammalian cells in "Advances in Pharmacology, Vol. 40" (August JT, Ed), Academic Press, California, 1997: 137-206.
47. Huyghe BG, Liu X, Sutjipto S, Sugarman BJ, Horn MT, Shepard HM, Scandella CJ and Shabram P. Purification of a type 5 recombinant adenovirus encoding human P53 by colum chromatography. Hum Gene Ther, 1995; 6: 1403-1416.
48. Sullivan NJ, Sanchez A, Rollin PE, Yang Z-Y and Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature, 2000, 408: 605-609.
49. Jaiswal S, Khanna N and Swaminathan S. A replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J Virol, 2003, In press.
50. Siemens RD, Elzey BD, Lubaroff DM, Bohlken C, Jensen RJ, Swanson AK and Ratliff TL. Restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol, 2001, 166: 731-735.
51. Yang Z-Y, Wyatts LS, Kong W-P, Moodie Z, Moss B and Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol, 2003, 77: 799-803.